These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
873 related articles for article (PubMed ID: 30062784)
1. Perampanel in routine clinical use in idiopathic generalized epilepsy: The 12-month GENERAL study. Villanueva V; Montoya J; Castillo A; Mauri-Llerda JÁ; Giner P; López-González FJ; Piera A; Villanueva-Hernández P; Bertol V; Garcia-Escrivá A; Garcia-Peñas JJ; Garamendi I; Esteve-Belloch P; Baiges-Octavio JJ; Miró J; Falip M; Garcés M; Gómez A; Gil-López FJ; Carreño M; Rodriguez-Uranga JJ; Campos D; Bonet M; Querol R; Molins A; Tortosa D; Salas-Puig J Epilepsia; 2018 Sep; 59(9):1740-1752. PubMed ID: 30062784 [TBL] [Abstract][Full Text] [Related]
2. PERPRISE: A prospective non-interventional study of PERampanel as only adjunctive treatment in patients with PRImary or SEcondarily generalized tonic-clonic seizures: First interim analysis. Steinhoff BJ; Goldmann T; Kockelmann E; Winter Y; Epilepsia Open; 2024 Jun; 9(3):926-939. PubMed ID: 38017663 [TBL] [Abstract][Full Text] [Related]
3. Perampanel for the treatment of people with idiopathic generalized epilepsy in clinical practice. Trinka E; Alsaadi T; Goji H; Maehara T; Takahashi S; Jacobs J; Renna R; Gil-López FJ; McMurray R; Sáinz-Fuertes R; Villanueva V Epilepsia; 2023 Aug; 64(8):2094-2107. PubMed ID: 37114853 [TBL] [Abstract][Full Text] [Related]
4. Perampanel as adjuvant treatment in epileptic encephalopathies: A multicenter study in routine clinical practice. Alonso-Singer P; Aguilar-Amat Prior MJ; Oliva-Navarro J; Massot-Tarrús A; Giráldez BG; Bermejo P; DeToledo-Heras M; Aledo-Serrano Á; Martínez-Cayuelas E; Tirado-Requero P; Velázquez-Fragua R; López-Sobrino G; Ojeda J Epilepsy Behav; 2022 Sep; 134():108836. PubMed ID: 35870432 [TBL] [Abstract][Full Text] [Related]
5. Retrospective study of perampanel efficacy and tolerability in myoclonic seizures. Gil-López FJ; Montoya J; Falip M; Aparicio J; López-González FJ; Toledano R; Gil-Nagel A; Molins A; García I; Serrano P; Domenech G; Torres F; Donaire A; Carreño M Acta Neurol Scand; 2018 Aug; 138(2):122-129. PubMed ID: 29573400 [TBL] [Abstract][Full Text] [Related]
6. Perampanel for tonic-clonic seizures in idiopathic generalized epilepsy A randomized trial. French JA; Krauss GL; Wechsler RT; Wang XF; DiVentura B; Brandt C; Trinka E; O'Brien TJ; Laurenza A; Patten A; Bibbiani F Neurology; 2015 Sep; 85(11):950-7. PubMed ID: 26296511 [TBL] [Abstract][Full Text] [Related]
7. Adjunctive perampanel and myoclonic and absence seizures: Post hoc analysis of data from study 332 in patients with idiopathic generalized epilepsy. Brandt C; Wechsler RT; O'Brien TJ; Patten A; Malhotra M; Ngo LY; Steinhoff BJ Seizure; 2020 Aug; 80():115-123. PubMed ID: 32563171 [TBL] [Abstract][Full Text] [Related]
8. Lamotrigine adjunctive therapy among children and adolescents with primary generalized tonic-clonic seizures. Trevathan E; Kerls SP; Hammer AE; Vuong A; Messenheimer JA Pediatrics; 2006 Aug; 118(2):e371-8. PubMed ID: 16847080 [TBL] [Abstract][Full Text] [Related]
9. Exploring the Evidence for Broad-Spectrum Effectiveness of Perampanel: A Systematic Review of Clinical Data in Generalised Seizures. Trinka E; Lattanzi S; Carpenter K; Corradetti T; Nucera B; Rinaldi F; Shankar R; Brigo F CNS Drugs; 2021 Aug; 35(8):821-837. PubMed ID: 34232492 [TBL] [Abstract][Full Text] [Related]
10. Safety, efficacy and outcome-related factors of perampanel over 12 months in a real-world setting: The FYDATA study. Villanueva V; Garcés M; López-González FJ; Rodriguez-Osorio X; Toledo M; Salas-Puig J; González-Cuevas M; Campos D; Serratosa JM; González-Giráldez B; Mauri JA; Camacho JL; Suller A; Carreño M; Gómez JB; Montoya J; Rodríguez-Uranga J; Saiz-Diaz R; González-de la Aleja J; Castillo A; López-Trigo J; Poza JJ; Flores J; Querol R; Ojeda J; Giner P; Molins A; Esteve P; Baiges JJ Epilepsy Res; 2016 Oct; 126():201-10. PubMed ID: 27521586 [TBL] [Abstract][Full Text] [Related]
11. Perampanel in routine clinical use across Europe: Pooled, multicenter, observational data. Rohracher A; Zimmermann G; Villanueva V; Garamendi I; Sander JW; Wehner T; Shankar R; Ben-Menachem E; Brodie MJ; Pensel MC; Di Gennaro G; Maurousset A; Strzelczyk A; Rheims S; Rácz A; Menzler K; Bertol-Alegre V; García-Morales I; López-González FJ; Toledo M; Carpenter KJ; Trinka E Epilepsia; 2018 Sep; 59(9):1727-1739. PubMed ID: 30047129 [TBL] [Abstract][Full Text] [Related]
12. Effectiveness and safety of perampanel monotherapy for focal and generalized tonic-clonic seizures: Experience from a national multicenter registry. Toledano Delgado R; García-Morales I; Parejo-Carbonell B; Jiménez-Huete A; Herrera-Ramirez D; González-Hernández A; Ayuga Loro F; Santamarina E; Toledo M; Ojeda J; Poza JJ; Molins A; Giner P; Estévez María JC; Castro-Vilanova MD; Zurita J; Saiz-Diaz RA; Gómez-Ibañez A; Rodriguez-Uranga J; Gil-Nagel A; Campos D; Sánchez-Larsen Á; Aguilar-Amat Prior MJ; Mauri Llerda JA; Huertas González N; García-Barragán N Epilepsia; 2020 Jun; 61(6):1109-1119. PubMed ID: 32511754 [TBL] [Abstract][Full Text] [Related]
13. Efficacy and tolerability of adjuvant perampanel: an Australian multicenter real-world observational study in refractory focal and generalized epilepsy syndromes. Sagar P; Wawryk O; Vogrin S; Whitham E; Kiley M; Frasca J; Carne R; Seneviratne U; Cook MJ; Lawn N; Nikpour A; D'Souza WJ Epilepsy Behav; 2021 Jun; 119():107935. PubMed ID: 33930626 [TBL] [Abstract][Full Text] [Related]
15. Perampanel for the treatment of primary generalized tonic-clonic seizures in idiopathic generalized epilepsy. Rohracher A; Brigo F; Höfler J; Kalss G; Neuray C; Dobesberger J; Kuchukhidze G; Leitinger M; Trinka E Expert Opin Pharmacother; 2016 Jul; 17(10):1403-11. PubMed ID: 27267634 [TBL] [Abstract][Full Text] [Related]
16. Effectiveness and tolerability of perampanel in children and adolescents with refractory epilepsies-An Italian observational multicenter study. De Liso P; Vigevano F; Specchio N; De Palma L; Bonanni P; Osanni E; Coppola G; Parisi P; Grosso S; Verrotti A; Spalice A; Nicita F; Zamponi N; Siliquini S; Giordano L; Martelli P; Guerrini R; Rosati A; Ilvento L; Belcastro V; Striano P; Vari MS; Capovilla G; Beccaria F; Bruni O; Luchetti A; Gobbi G; Russo A; Pruna D; Tozzi AE; Cusmai R Epilepsy Res; 2016 Nov; 127():93-100. PubMed ID: 27568598 [TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of perampanel in generalized and focal to bilateral tonic-clonic seizures: A comparative study of Asian and non-Asian populations. Nishida T; Lee SK; Wu T; Tiamkao S; Dash A Epilepsia; 2019 Mar; 60 Suppl 1():47-59. PubMed ID: 30869168 [TBL] [Abstract][Full Text] [Related]
18. Open-label study to investigate the safety and efficacy of adjunctive perampanel in pediatric patients (4 to <12 years) with inadequately controlled focal seizures or generalized tonic-clonic seizures. Fogarasi A; Flamini R; Milh M; Phillips S; Yoshitomi S; Patten A; Takase T; Laurenza A; Ngo LY Epilepsia; 2020 Jan; 61(1):125-137. PubMed ID: 31912493 [TBL] [Abstract][Full Text] [Related]
19. Effectiveness and safety of perampanel as early add-on treatment in patients with epilepsy and focal seizures in the routine clinical practice: Spain prospective study (PERADON). Abril Jaramillo J; Estévez María JC; Girón Úbeda JM; Vega López Ó; Calzado Rivas ME; Pérez Díaz H; García Martín G; Vila Herrero E; Chamorro-Muñoz M; Vázquez F; De la Fuente C; Redondo L; Peláez N; Santágueda P; Rodríguez Uranga JJ Epilepsy Behav; 2020 Jan; 102():106655. PubMed ID: 31812902 [TBL] [Abstract][Full Text] [Related]
20. Safety and efficacy of perampanel in children and adults with various epilepsy syndromes: A single-center postmarketing study. Singh K; Shah YD; Luciano D; Friedman D; Devinsky O; Kothare SV Epilepsy Behav; 2016 Aug; 61():41-45. PubMed ID: 27300147 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]